TransCelerate Aims to Ease Trial Comparator Sourcing

By Zachary Brennan

- Last updated on GMT

TransCelerate Aims to Ease Trial Comparator Sourcing
TransCelerate Aims to Ease Trial Comparator Sourcing

Related tags Clinical trial Contract research organization Pharmacology

The TransCelerate BioPharma industry group has launched its clinical trial comparator network to establish a reliable means for sourcing quality drugs for clinical trials. 

Sponsors’ current means of acquiring clinical trial comparator drugs and co-therapy drugs are inefficient and unpredictable, according to TransCelerate, which is made up of 10 of the largest biopharma companies, including Pfizer, Roche and Sanofi.  When comparators and co-therapies are purchased on the open market, it can lead to supply disruptions and timeline delays.

Terry Walsh, RPh, MBA, head of the comparator network initiative for TransCelerate, told, “The network will allow us to take the process of accessing comparators (standard of care, rescue, and comparator medicines) off the critical path of study start up.  Accessing the medicines through the network, when the sponsor company needs them will allow the sponsor to plan accordingly and focus on other activities needed to start a study​.” 

The comparator network may be similar to agreements made between two companies before a study starts. 

Prior to the creation of the network, some companies created study-specific bilateral agreements, which provided similar benefits and impact as the network​,” Walsh told us. “However, the agreements were customized each time two companies worked together and could take up to nine months to negotiate,​” where as this will all be set up prior to any new study start. 

How it Will Work​ 

Although the network is set up for all member companies, only the manufacturers and sponsors will share the necessary information for each trial. 

The network will not share one member company’s demand data with the entire network,​” Walsh explained.   

As the members receive the forecasts from the other members who need their products, this will be better enable the member companies’ commercial units to develop supply chain forecasts, which will decrease the incidences of supply disruption (e.g., it decreases the risk of a vendor going into a region and buying up all the product to use in a clinical trial)​.”  

Sponsors will also now know they can access the medication when it is needed, “as opposed to buying product whenever it is available and no guarantee of future access​,” Walsh said.  

Benefit to CROs 

The creation of the comparator network will also be a boon for CROs (contract research organizations) because of the possibility of sponsors using their supply chain savings to conduct more trials. 

Walsh noted, “CROs will benefit as the industry benefits. If we reduce inefficiency and hence save cost, we can develop more drugs – and as a result – conduct more clinical trials. The vast majority of these industry trials are conducted by CROs​.”

Related news

Show more

Related products

show more

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

Designing an Optimal APAC Clinical Supply Chain

Designing an Optimal APAC Clinical Supply Chain

Catalent | 08-Mar-2023 | Infographic

With clinical study activity increasing across the Asia-Pacific region, it is important for sponsors—both in APAC and globally—to understand the broader...

Related suppliers

Follow us


View more